22 July 2010 
EMA/CHMP/429539/2010  
Committee for medicinal products for human use (CHMP) 
Summary of opinion1 (post authorisation) 
Arixtra 
Fondaparinux sodium 
On 22 July 2010 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a variation to the terms of the marketing authorisation for the medicinal 
product Arixtra. The marketing authorisation holder for this medicinal product is Glaxo Group Ltd. They 
may request a re-examination of the CHMP opinion, provided that they notify the European Medicines 
Agency in writing of their intention within 15 days of receipt of the opinion. 
The CHMP adopted a new indication for Arixtra 1.5mg/0.3ml and 2.5mg/0.5ml as follows: 
“Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower 
limbs without concomitant deep-vein thrombosis”. 
Detailed conditions for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after the variation to the 
marketing authorisation has been granted by the European Commission. 
For information, the full indications for Arixtra will be as follows2: 
Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe 
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of 
the lower limbs such as hip fracture, major knee surgery or hip replacement surgery. 
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are 
judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal 
cancer surgery (see section 5.1). 
Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at 
high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or 
acute respiratory disorders, and/or acute infectious or inflammatory disease.  
1 Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued 
within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion. 
2 The text in bold represents the new or the amended indication. 
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom 
Telephone  +44 (0)20 7418 8400  Facsimile +44 (0)20 7418 8613 
E-mail  info@ema.europa.eu  Website  www.ema.europa.eu 
An agency of the European Union   
© European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
                                               
 
 
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the 
lower limbs without concomitant deep-vein thrombosis (see sections 4.2 and 5.1).  
Arixtra 2.5 mg/0.5 ml solution for injection, pre-filled syringe 
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of 
the lower limbs such as hip fracture, major knee surgery or hip replacement surgery. 
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are 
judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal 
cancer surgery (see section 5.1). 
Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at 
high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or 
acute respiratory disorders, and/or acute infectious or inflammatory disease.  
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in 
adultsfor whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4.4 
and 5.1). 
Treatment of ST segment elevation myocardial infarction (STEMI) in adults who are managed with 
thrombolytics or who initially are to receive no other form of reperfusion therapy.  
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the 
lower limbs without concomitant deep-vein thrombosis (see sections 4.2 and 5.1).  
Indications for Arixtra 5 mg/0.4 ml solution for injection, pre-filled syringe and Arixtra 7.5 mg/0.6 ml 
solution for injection, pre-filled syringe remained unchanged. 
Arixtra  
EMA/CHMP/429539/2010  
Page 2/2
 
 
 
 
 
 
 
 
 
 
 
 
 
